Allogeneic bone marrow-derived mesenchymal stem cell therapy (Pharmicell)

N/A

Report date: 2024/10/29 14:24:41

Base Information

Drug NameAllogeneic bone marrow-derived mesenchymal stem cell therapy (Pharmicell)
Drug Alias NameCellgram-CKD (Pharmicell)
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapy
Mechanisms of ActionStem cell replacements
TargetsUpdating
Therapy Area/IndicationsRenal Insufficiency, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesPharmicell Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesPharmicell Co Ltd
Inactive CompaniesN/A
Active IndicationsRenal Insufficiency, Chronic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A